mTOR Inhibitor and Thyroid Hormone Composition for Brain Injury
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acquired brain injury (ABI), traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), and degenerative neurological disorders such as Alzheimer's and Parkinson's Disease are limited in efficacy, particularly due to delayed administration of anti-inflammatory and neuroprotective drugs, and lack effective solutions for reducing inflammation and cellular damage.
Innovation Solution
A pharmaceutical composition comprising one or more mTOR inhibitors, optionally combined with thyroid hormones, is administered to treat ABI, TBI, PTSD, and other disorders, aiming to reduce inflammation, enhance neuronal integrity, and induce apoptosis in senescent cells, thereby addressing the underlying causes of these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-inflammatory and neuroprotective drugs are administered immediately after injury, then therapeutic effect is significant, but treatment window is extremely limited and difficult to achieve in clinical practice
Solution Approach 1:
The patent employs preliminary action by pre-administering or pre-positioning therapeutic agents (mTOR inhibitors and thyroid hormones) that can act immediately when administered, even at delayed time points. The composition is designed to be ready-for-use and stable, allowing clinicians to administer it as soon as possible within the extended therapeutic window without requiring perfect timing from injury onset.
2Reliability
If mTOR inhibitors and thyroid hormones are combined, then neuroprotective efficacy is enhanced, but formulation complexity increases
Solution Approach 1:
The patent merges two distinct therapeutic agents (mTOR inhibitors and thyroid hormones) into a single pharmaceutical composition. This combination approach allows both agents to work synergistically—mTOR inhibitors reduce inflammation and cellular damage while thyroid hormones support neuronal metabolism and survival—thereby enhancing overall neuroprotective efficacy while simplifying administration compared to separate therapies.
3Reliability
If treatment targets multiple pathways (inflammation, cellular stability, neuronal function), then comprehensive protection is achieved, but mechanism complexity increases
Solution Approach 1:
The pharmaceutical composition exhibits multi-functionality by simultaneously addressing multiple pathological mechanisms through its two active components. The mTOR inhibitor component targets inflammation and cellular stability pathways, while the thyroid hormone component supports neuronal metabolism, protein synthesis, and survival. This universal approach allows a single composition to provide comprehensive neuroprotection across multiple disease mechanisms without requiring separate targeted therapies.
Data Source
AI summary
Disclosed herein are pharmaceutical compositions for the treatment of acquired brain injury (ABI), including traumatic brain injury (TBI) and acute non-traumatic brain injury (ANBI), post-traumatic stress disorder (PTSD), and other degenerative neurological disorders that may or may not be associated with ABI comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating, preventing, reducing the intensity of or reducing the severity of ABI and/or PTSD, the method comprising administering an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.